Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
- None.
- None.
The FDA's clearance of Corbus Pharmaceuticals' investigational new drug application for CRB-601 marks a significant milestone in the field of precision oncology. CRB-601's mechanism, which involves blocking the activation of latent Transforming Growth Factor beta (TGFβ) by targeting integrin αvβ8, is an innovative approach to modulate the tumor microenvironment. This strategy aims to enhance immune system penetration and activity within tumors, potentially overcoming the immune exclusion that is a major hurdle in cancer treatment.
The pre-clinical data suggesting that CRB-601 can potentiate the effects of immune checkpoint inhibitors, particularly anti-PD-1 therapy, is promising. This could signify a leap forward in combination therapies for solid tumors. The initiation of a Phase 1 clinical trial is the next critical step in evaluating the safety, tolerability and preliminary efficacy of CRB-601 in humans. If successful, this could lead to a new therapeutic option for patients with solid tumors resistant to current PD(L)-1 targeted therapies.
From a research and development perspective, the progression of CRB-601 into Phase 1 clinical trials is an indicator of Corbus Pharmaceuticals' commitment to expanding its oncology pipeline. The pre-clinical data presented at the Society for Immunotherapy of Cancer meeting provides a strong scientific rationale for the clinical development of CRB-601. The potential 'best-in-class' designation implies that CRB-601 may offer advantages over existing TGFβ inhibitors, such as improved efficacy or safety profiles.
Investors and stakeholders should monitor the enrollment and progression of the Phase 1 trial closely. Early-stage clinical trials are inherently risky and the outcome will have significant implications for the company's valuation. A successful trial could lead to increased investor confidence and potential partnerships or funding opportunities, whereas any setbacks could negatively impact the company's financial health and stock performance.
The FDA's approval for the Phase 1 study of CRB-601 is a critical event for Corbus Pharmaceuticals, with potential financial implications. The transition from pre-clinical to clinical stages often serves as a catalyst for biotech stocks, as it signifies a step closer to market approval and revenue generation. However, the biotech sector is highly speculative and the company's stock price may fluctuate significantly based on the perceived success or failure of the drug's development.
Given the competitive landscape of oncology drugs, a successful entry of CRB-601 into the market could disrupt existing treatment paradigms and capture a significant market share. On the flip side, the high costs associated with drug development, particularly in the oncology space, mean that any delays or negative results from the Phase 1 trials could pose substantial financial risks to Corbus. Investors should consider the company's cash runway and the potential need for additional capital to fund future trials.
- CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment
- Phase 1 clinical study set to commence H1 2024
- Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models
NORWOOD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo. The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
“Pre-clinical data generated to-date demonstrates that CRB-601 has robust anti-tumor activity as monotherapy and in combination with anti-PD-1 therapy in a variety of solid tumors exhibiting a range of sensitivities to PD(L)-1 targeted therapy,” said Yuval Cohen Ph.D., Chief Executive Officer of Corbus. “CRB-601 blocked latent TGFβ activation and enhanced immune cell penetration into the tumor microenvironment in pre-clinical models. We believe this mechanism of action is complimentary to the effects of anti PD(L)-1 therapy leading to enhanced combinatorial efficacy. We look forward to initiating our Phase 1 First-in-Human trial of CRB-601 and anticipate enrolling the first participant in the first half of this year.”
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What is the name of the precision oncology company mentioned in the press release?
What is the ticker symbol of Corbus Pharmaceuticals Holdings, Inc.?
What is CRB-601?
When is the Phase 1 clinical study for CRB-601 set to commence?
What did the pre-clinical data demonstrate about CRB-601?
Who is the Chief Executive Officer of Corbus Pharmaceuticals Holdings, Inc.?
What did Yuval Cohen Ph.D. say about CRB-601?
What is the mechanism of action of CRB-601?
When does the Company anticipate enrolling the first participant in the Phase 1 trial of CRB-601?
